Orforglipron Research for Type 2 Diabetes
An evidence-based overview of research examining Orforglipron in the context of type 2 diabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
ATTAIN-2 evaluated orforglipron in adults with obesity and type 2 diabetes, showing statistically significant improvements in HbA1c and all prespecified weight and cardiometabolic measures with the 36mg dose vs placebo at 72 weeks. The oral administration without food restrictions offers practical advantages over existing therapies. Two further phase 3 trials published in 2026 extend the diabetes evidence: ACHIEVE-2 tested orforglipron against dapagliflozin as an add-on to metformin and met non-inferiority on the treatment-regimen estimand, and ACHIEVE-5 tested it as an add-on to titrated insulin glargine. ACHIEVE-J (PMID 42607698) is an open-label Phase 3 safety trial (n=401, 52 weeks), not a weight-loss headline; the abstract does not report a treatment-regimen HbA1c or weight-change figure. Orforglipron remains unapproved for type 2 diabetes.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.